| | Characteristic | Value |
| | Patient related | | | Female, (%) | 153 (81.0) | | Postmenopausal, (%) | 59 (31.2) | | Time since menopause, mean (SD), years | 7.330 (8.275) | | Age, mean (SD), years | 53.340 (11.502) | | BMI, mean (SD), kg/m2 | 27.150 (4.768) | | Ever smokers, (%) | 24 (12.7) | | Hypertension, (%) | 39 (20.6) | | Diabetes mellitus, (%) | 14 (7.4) | | Dyslipidemia, (%) | 23 (12.2) | | Disease related | | | Disease duration, mean (SD), years | 13.72 (9.955) | | RF positivity, (%) | 115 (60.847) | | Anti-CCP antibodies positivity, (%) | 152 (80.423) | | DAS28 (4V), mean (SD) | 4.266 (1.324) | | Remission (DAS28 (4v) < 2.6) | 18 (9.5) | | Low (2.6 < DAS28 (4v) ≤ 3.2) | 27 (14.3) | | Moderate (3.2 < DAS28 (4V) ≤ 5.1) | 95 (50.3) | | High (DAS28 (4v) > 5.1) | 49 (25.9) | | ESR, mean (SD), mm (first hour) | 27.100 (20.603) | | CRP, mean (SD), mg/L | 11.573 (20.045) | | Global health on VAS, mean (SD) | 44.190 (17.794) | | HAQ score, mean (SD) | 1.275 (0.708) | | RA related treatment | | | Corticosteroids, (%) | 155 (82.0) | | Daily dose in prednisolone equivalents, mean (SD), mg | 5.139 (3.977) | | Time under corticosteroids, mean (SD), years | 11.429 (8.981) | | NSAIDs, (%) | 142 (75.1) | | DMARDS, (%) | 160 (84.7) | | Cumulative, mean (SD) | 2.534 (1.416) | | Time under DMARDs, mean (SD), months | 104.037 (87.714) | | Methotrexate, (%) | 130 (68.8) | | Leflunomide, (%) | 40 (21.1) | | Biologic DMARDs, (%) | 97 (51.3) | | Time under biologics, mean (SD), months | 60.258 (30.080) | | Anti-TNFα blockers, (%) | 83 (43.9) | | Non-anti-TNFα blockers, (%) | 14 (7.4) | | Bisphosphonates, (%) | 69 (36.5) | | Cardiovascular related treatment | | | Antiaggregants, (%) | 22 (11.6) | | ACEIs, (%) | 24 (12.7) | | ARAs, (%) | 24 (12.7) | | CCAs, (%) | 18 (9.5) | | BBs, (%) | 15 (7.9) | | Diuretics, (%) | 37 (19.6) | | Warfarin, (%) | 5 (2.6) | | Statins, (%) | 45 (23.8) | | Oral antidiabetic agents, (%) | 17 (9.0) | | Insulin, (%) | 5 (2.6) |
|
|
ACEIs, angiotensin converter enzyme inhibitors; ARAs, angiotensin receptor antagonists; BBs, beta-blockers; BMI, body mass index; CCAs, calcium channel antagonists; CCP, cyclic citrullinated peptides; CRP, c-reactive protein; DAS, disease activity score; DMARDS, disease-modifying antirheumatic dugs; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; NSAIDs, nonsteroidal anti-inflammatory drugs; RF, rheumatoid factor; SD, standard deviation; TNFα, tumour necrosis factor alpha; VAS, visual analogic scale.
|
